U.S. FDA Adds Boxed Warning on Invokana Label Over Increased Risk of Foot/Leg Amputations

☞ | View the text of this post. Exclusively available to ASQ Members.

The U.S. Food and Drug Administration (FDA) has announced that it will be imposing new warnings, including a Boxed Warning, on canagliflozin products including Invokana, Invokamet, Invokamet XR (all marketed by Johnson & Johnson, J&J; U.S.) in light of new safety concerns observed in two large clinical trials (CANVAS and CANVAS-R). The prescription drugs are indicated for the treatment of type 2 diabetes, and were found to double the chances of leg and foot amputations

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *